Eric Devroe Biography and Net Worth

Eric Devroe, Ph.D., is Chief Operating Officer at Acrivon Therapeutics, Inc. Eric is an executive and entrepreneur with significant experience helping found, launch, and build new life science companies. Most recently, he served as Founder & CEO of Xione Therapeutics, Inc., an oncology focused spin-out of The University of Texas MD Anderson Cancer Center. Prior to Xione, he was Strategic Advisor, Therapeutics Discovery at MD Anderson Cancer Center, and the Founder and CEO of Opsonix, Inc., an infectious disease focused spin-out of the Wyss Institute at Harvard University. Prior to Opsonix, he served as Executive Director of Strategic Alliances at MD Anderson Cancer Center. Earlier in his career he served as VP, Business & Strategy Development at Metamark Genetics, Inc., and an Associate at Flagship Pioneering. He holds a B.S. in Microbiology from the University of Texas at Austin and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

What is Eric Devroe's net worth?: The estimated net worth of Eric Devroe is at least $271.48 thousand as of August 18th, 2026. Devroe owns 146,349 shares of Acrivon Therapeutics stock worth more than $271,477 as of September 18th. This net worth evaluation does not reflect any other assets that Devroe may own. Learn More about Eric Devroe's net worth.
How do I contact Eric Devroe?: The corporate mailing address for Devroe and other Acrivon Therapeutics executives is 480 Arsenal Way, Suite 100, Watertown, MA, 02472. Acrivon Therapeutics can also be reached via phone at 617-207-8979 and via email at [email protected]. Learn More on Eric Devroe's contact information.
Has Eric Devroe been buying or selling shares of Acrivon Therapeutics?: In the last ninety days, Eric Devroe has sold $1,214.04 of Acrivon Therapeutics stock. Most recently, Eric Devroe sold 604 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $2.01, for a transaction totalling $1,214.04. Following the completion of the sale, the chief operating officer now directly owns 146,349 shares of the company's stock, valued at $294,161.49. Learn More on Eric Devroe's trading history.
Who are Acrivon Therapeutics' active insiders?: Acrivon Therapeutics' insider roster includes Peter Blume-Jensen (CEO), and Eric Devroe (COO). Learn More on Acrivon Therapeutics' active insiders.
Are insiders buying or selling shares of Acrivon Therapeutics?: In the last twelve months, Acrivon Therapeutics insiders bought shares 3 times. They purchased a total of 67,832 shares worth more than $114,534.40. In the last twelve months, insiders at the sold shares 7 times. They sold a total of 18,253 shares worth more than $38,850.00. The most recent insider tranaction occured on August, 25th when CEO Peter Blume-Jensen sold 14,036 shares worth more than $31,019.56. Insiders at Acrivon Therapeutics own 10.5% of the company. Learn More about insider trades at Acrivon Therapeutics.
Information on this page was last updated on 8/25/2026.

Eric Devroe Insider Trading History at Acrivon Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/18/2026	Sell	604	$2.01	$1,214.04	146,349
1/13/2026	Buy	10,000	$1.72	$17,200.00	75,308

Eric Devroe Buying and Selling Activity at Acrivon Therapeutics

Acrivon Therapeutics Company Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Today's Range

Now: $1.85

$1.69

$1.87

50 Day Range

MA: $1.88

$1.43

$2.39

2 Week Range

Now: $1.85

$1.27

$3.56

Volume

319,958 shs

Average Volume

918,093 shs

Market Capitalization

$79.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92